Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

ConclusionsDespite a doubled maximum concentration with weekly iniparib, no detectable differences in safety or efficacy were observed between the weekly and twice-weekly administration schedules in this population.Trial registrationClinicalTrial.gov Identifier NCT01045304.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research